查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984885

全球标靶癌症治疗市场：按疾病、治疗方法、最终用户和地区分析—市场规模、行业趋势、机会分析和未来预测（2026-2035 年）

Global Targeted Cancer Therapy Market: Analysis by Disease Indication, Therapy Type, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

标靶癌症治疗市场需求强劲，成长显着，预计2025年市场规模将达908.9亿美元。据预测，未来十年该市场规模将成长近一倍，到2035年将达到惊人的1,754.8亿美元。这一增长意味着2026年至2035年预测期内的复合年增长率将达到6.80%，反映了标靶癌症治疗在全球范围内的快速发展和日益普及。

多种因素推动了这一上升趋势，但其中最重要的是精准肿瘤学的进步。精准肿瘤学透过实现针对个别肿瘤独特分子和基因特征的个人化治疗，彻底改变了癌症治疗。这种个人化治疗提高了疗效并最大限度地减少了副作用，使标靶治疗对临床医生和患者都更具吸引力。抗体药物复合体（ADC）的创新也发挥了至关重要的作用。 ADC结合了单株抗体的标靶化能力和强效细胞毒性药物，能够将杀死癌细胞的药物直接且高度选择性地递送至癌细胞。

显着的市场趋势

标靶癌症治疗市场的竞争格局由大型製药企业主导，这些公司正积极透过策略性收购和投资来巩固自身地位。Astra Zeneca凭藉其大获成功的Enhertu系列产品，在抗体药物复合体（ADC）领域占据主导地位。该产品组合使Astra Zeneca处于创新标靶治疗的前沿，该公司已在该领域获得显着的市场份额，并正引领市场成长。

诺华是另一家在放射性药物领域取得显着进展的主要企业。其积极的扩张步伐体现在近期的收购中，例如以29亿美元收购Morphosys以及以17.5亿美元收购Mariana Oncology。这些投资凸显了诺华致力于推动放射性药物技术发展并拓展其靶向癌症疗法产品线的决心，从而巩固了其在该新兴领域的领先地位。

2024年，百时美施贵宝（BMS）斥资41亿美元收购RayzBio，此举备受瞩目。此次收购巩固了BMS在锕系治疗方法领域的战略地位。锕系疗法是一种极具前景的标靶癌症治疗领域，它利用放射性同位素将强效治疗作用直接传递至癌细胞。此交易不仅拓展了BMS的治疗能力，也增强了其在肿瘤市场的竞争优势。

主要成长要素

标靶癌症治疗市场正经历显着成长，这主要得益于全球癌症发生率的上升。由于人口老化、生活方式改变和环境因素的影响，癌症发生率持续攀升，对创新有效治疗方法的需求比以往任何时候都更加迫切。患者和医疗专业人员越来越倾向于寻求能够提高存活率并改善生活品质的治疗方法，同时尽可能减少传统癌症治疗中常见的严重副作用。

新机会的趋势

标靶癌症治疗是肿瘤学领域一项突破性的变革。它标誌着治疗方式从传统化疗的广泛且特异性方法，转向一种被称为精准医疗的更精准和个人化的治疗模式。传统化疗透过不加选择地攻击体内快速增殖的细胞来发挥作用，但不幸的是，这不仅包括癌细胞，还包括毛囊、消化道和骨髓中的健康细胞。这种缺乏特异性会导致广泛的全身性毒性以及许多副作用，例如脱髮、噁心和免疫功能减弱，从而可能严重影响患者的生活品质。

优化障碍

标靶治疗的高成本是其广泛应用的主要障碍，尤其是在中低收入国家，这可能会阻碍整体市场成长。部分标靶治疗方法的费用高达每次疗程90万美元以上，反映了其研发、生产和治疗的复杂性。如此高昂的价格使得许多医疗预算有限、健保覆盖不足或缺失的患者难以负担这些创新治疗方法。这项经济挑战限制了这些国家医疗系统大规模推广标靶治疗的能力，阻碍了患者获得能够显着改善治疗效果的前沿癌症疗法。

目录

第一章执行摘要：全球标靶癌症治疗市场

第二章：报告概述

  • 研究框架
    • 研究目标
    • 市场的定义
    • 市场区隔
  • 调查方法
    • 市场规模估算
    • 定性研究
    • 量化研究
    • 初步调查受访者组成：依地区划分
    • 数据检验
    • 调查的前提

第三章：全球标靶癌症治疗市场概览

  • 产业价值链分析
    • 标靶识别和生物标记发现
    • 生物製药製造商
    • 契约製造和CRO服务
    • 分销和专业药房网络
    • 医院及癌症治疗中心
  • 产业展望
    • 精准肿瘤学应用趋势
    • 研发管线趋势与临床试验活动
    • 监理和药品核准趋势
    • 定价和兑换环境
    • 生技药品生产和供应链的发展趋势
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场成长及前景
    • 市场获利估算与预测（2020-2035）
    • 依治疗方法进行价格趋势分析
  • 市场吸引力分析
  • 可执行的见解（分析师建议）

第四章：竞争对手仪錶板

  • 市场集中度
  • 企业市场占有率分析（2025 年）
  • 竞争格局分析与基准测试
    • 主要企业- 按地区

第五章：全球标靶癌症治疗市场分析

  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场机会概述
  • 透过治疗方法
    • 关键见解
    • 市场规模及预测（2020-2035）
  • 疾病特异性
    • 关键见解
    • 市场规模及预测（2020-2035）
  • 最终用户
    • 关键见解
    • 市场规模及预测（2020-2035）
  • 按地区
    • 关键见解
    • 市场规模及预测（2020-2035）

第六章：北美标靶癌症治疗市场分析

第七章：欧洲标靶癌症治疗市场分析

第八章：亚太地区标靶癌症治疗市场分析

第九章：中东和非洲标靶癌症治疗市场分析

第十章：南美洲标靶癌症治疗市场分析

第十一章：公司简介

  • Agenus, Inc.
  • Amgen, Inc.
  • Arcus Biosciences, Inc.
  • AstraZeneca Plc.
  • Aurinia Pharmaceuticals Inc.
  • Celdara Medical LLC
  • F. Hoffmann-La Roche &Co.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Nektar Therapeutics Inc.
  • Pfizer, Inc.
  • Serena Therapeutics Inc.
  • 其他主要企业

第十二章附录

简介目录
Product Code: AA02261698

The targeted cancer therapy market is experiencing robust demand and significant growth, with its value estimated at USD 90.89 billion in 2025. Projections indicate that this market will nearly double over the next decade, reaching an impressive valuation of USD 175.48 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 6.80% during the forecast period from 2026 to 2035, reflecting the dynamic evolution and increasing adoption of targeted cancer treatments worldwide.

Several factors are fueling this upward trajectory, chief among them being advancements in precision oncology. Precision oncology has revolutionized cancer treatment by enabling therapies tailored to the unique molecular and genetic profiles of individual tumors. This personalization increases treatment efficacy while minimizing adverse effects, making targeted therapies more attractive to both clinicians and patients. Innovations in antibody-drug conjugates (ADCs) also play a pivotal role. ADCs combine the targeting capabilities of monoclonal antibodies with potent cytotoxic agents, allowing for highly selective delivery of cancer-killing drugs directly to tumor cells.

Noteworthy Market Developments

The competitive landscape of the targeted cancer therapy market is dominated by major pharmaceutical corporations that are actively strengthening their positions through strategic acquisitions and investments. AstraZeneca stands out as a dominant force, especially in the antibody-drug conjugate (ADC) segment, with its highly successful Enhertu franchise. This portfolio has positioned AstraZeneca at the forefront of innovative targeted therapies, enabling the company to capture significant market share and drive growth in this specialized area.

Novartis is another key player making substantial strides in the radiopharmaceutical sector. The company's aggressive expansion is highlighted by its recent acquisitions, including a USD 2.9 billion purchase of MorphoSys and a USD 1.75 billion acquisition of Mariana Oncology. These investments underscore Novartis's commitment to advancing radiopharmaceutical technologies and expanding its pipeline of targeted cancer treatments, reinforcing its leadership in this emerging field.

Bristol Myers Squibb (BMS) made a high-profile move in 2024 by acquiring RayzeBio for USD 4.1 billion. This acquisition secured BMS a strategic foothold in actinium-based therapies, a promising area of targeted cancer treatment that utilizes radioactive isotopes to deliver potent therapeutic effects directly to cancer cells. This deal not only expands BMS's therapeutic capabilities but also strengthens its competitive edge in the oncology market.

Core Growth Drivers

The market for targeted cancer therapies is experiencing significant growth driven primarily by the increasing incidence of cancer worldwide. As cancer rates continue to rise due to factors such as aging populations, lifestyle changes, and environmental influences, the demand for innovative and effective treatment options has become more urgent than ever. Patients and healthcare providers alike are seeking therapies that can not only improve survival rates but also enhance quality of life by minimizing the debilitating side effects often associated with traditional cancer treatments.

Emerging Opportunity Trends

Targeted cancer therapy marks a significant and transformative shift in the field of oncology, moving away from the broad, non-specific approach traditionally embodied by chemotherapy toward a more precise and individualized form of treatment known as precision medicine. Conventional chemotherapy operates by attacking rapidly dividing cells throughout the body without discrimination, which unfortunately includes not only cancer cells but also healthy cells found in hair follicles, the gastrointestinal tract, and bone marrow. This lack of specificity leads to widespread systemic toxicity, resulting in numerous side effects such as hair loss, nausea, and compromised immune function, which can severely impact a patient's quality of life.

Barriers to Optimization

The high cost of targeted therapies presents a significant barrier to widespread access, particularly in low-to middle-income countries, which could potentially impede overall market growth. Some of these therapies are priced at over $900,000 per treatment, reflecting the complexity of their development, manufacturing, and administration. Such steep price points place these innovative treatments out of reach for many patients in regions where healthcare budgets are limited, and insurance coverage is often insufficient or nonexistent. This economic challenge restricts the ability of healthcare systems in these countries to adopt targeted therapies on a large scale, limiting patient access to cutting-edge cancer treatments that could significantly improve outcomes.

Detailed Market Segmentation

Based on therapy, monoclonal antibodies are poised to capture a commanding position in the targeted cancer therapy market, expected to generate over 43% of the total revenue share. This strong financial dominance is rooted in their remarkable biological versatility, which allows these agents to serve multiple therapeutic functions. Initially developed as direct inhibitors targeting specific cancer cell markers, monoclonal antibodies have evolved to play critical roles as immune checkpoint inhibitors, effectively enhancing the body's immune response against tumors. Additionally, they are increasingly utilized as delivery vehicles for cytotoxic payloads, enabling the precise targeting and destruction of cancer cells while minimizing damage to healthy tissues.

Based on disease indication, Lung cancer has emerged as the leading disease indication within the targeted cancer therapy market, commanding more than 32% of the total market share. This dominance directly reflects the significant global burden posed by lung cancer, which remains the foremost cause of cancer-related mortality worldwide. Accounting for approximately 18.7% of all cancer deaths, lung cancer's impact is profound and far-reaching, underscoring the urgent need for effective treatment options.

Based on end user, hospitals represent the largest end-user segment in the targeted cancer therapy market, accounting for 58% of the total market share. This dominant position is largely due to the critical infrastructure hospitals provide for managing high-value biologics, many of which require specialized infusion protocols that can only be safely and effectively administered in a clinical setting. For instance, supportive care biologics such as Infliximab are predominantly delivered within hospital environments. This particular biologic is significant not only for its therapeutic role but also because it contributes to 32% of the overall biosimilar revenue, highlighting the financial and clinical importance of hospital-based administration.

Segment Breakdown

By Disease Indication

  • Colorectal Cancer
  • Breast Cancer
  • Gastrointestinal
  • Lung Cancer
  • Others

By Therapy Type

  • Signal Transduction Inhibitors
  • Monoclonal Antibodies
  • Small Molecule Inhibitors
  • Hormone Therapies
  • Others

By End-User

  • Cancer and Radiation Therapy Centers
  • Hospitals
  • Clinics

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America holds a commanding 39% share of the targeted cancer therapy market, a leadership position largely driven by the highly supportive regulatory environment in the United States. In 2024 alone, the U.S. Food and Drug Administration (FDA) approved 15 oncology drugs, signaling a robust pipeline of innovative treatments and creating an attractive landscape for investment and rapid commercialization. This proactive regulatory approach has been instrumental in fostering confidence among pharmaceutical companies and investors, encouraging them to accelerate their development and market entry efforts.
  • Capitalizing on this favorable environment, major industry players have made significant strategic moves to strengthen their foothold in the market. For example, Bristol Myers Squibb invested USD 4.1 billion to acquire RayzeBio, a move aimed at securing crucial radiopharmaceutical assets within the United States. This acquisition not only enhances Bristol Myers Squibb's portfolio but also underscores the importance of owning key therapeutic technologies domestically, aligning with broader industry trends prioritizing innovation and market access in North America.

Leading Market Participants

  • Agenus, Inc.
  • Amgen, Inc.
  • Arcus Biosciences, Inc.
  • AstraZeneca Plc.
  • Aurinia Pharmaceuticals Inc.
  • Celdara Medical LLC
  • F. Hoffmann-La Roche & Co.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Nektar Therapeutics Inc.
  • Pfizer, Inc.
  • Serena Therapeutics Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Targeted Cancer Therapy Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Targeted Cancer Therapy Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Target Identification & Biomarker Discovery
    • 3.1.2. Biopharmaceutical Manufacturers
    • 3.1.3. Contract Manufacturing & CRO Services
    • 3.1.4. Distribution & Specialty Pharmacy Networks
    • 3.1.5. Hospitals & Oncology Treatment Centers
  • 3.2. Industry Outlook
    • 3.2.1. Precision Oncology Adoption Trends
    • 3.2.2. Pipeline Landscape & Clinical Trial Activity
    • 3.2.3. Regulatory & Drug Approval Trends
    • 3.2.4. Pricing & Reimbursement Environment
    • 3.2.5. Biologics Manufacturing & Supply Chain Trends
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Therapy Type
  • 3.6. Market Attractiveness Analysis
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking
    • 4.3.1. Key players - By Region

Chapter 5. Global Targeted Cancer Therapy Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Opportunity Snapshot
  • 5.3. By Therapy Type
    • 5.3.1. Key Insights
    • 5.3.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.3.2.1. Monoclonal Antibodies
      • 5.3.2.2. Small Molecule Inhibitors
      • 5.3.2.3. Signal Transduction Inhibitors
      • 5.3.2.4. Hormone Therapies
      • 5.3.2.5. Others
  • 5.4. By Disease Indication
    • 5.4.1. Key Insights
    • 5.4.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.4.2.1. Lung Cancer
      • 5.4.2.2. Breast Cancer
      • 5.4.2.3. Colorectal Cancer
      • 5.4.2.4. Gastrointestinal Cancer
      • 5.4.2.5. Others
  • 5.5. By End User
    • 5.5.1. Key Insights
    • 5.5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.5.2.1. Hospitals
      • 5.5.2.2. Cancer & Radiation Therapy Centers
      • 5.5.2.3. Clinics
  • 5.6. By Region
    • 5.6.1. Key Insights
    • 5.6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
      • 5.6.2.1. North America
        • 5.6.2.1.1. The U.S.
        • 5.6.2.1.2. Canada
        • 5.6.2.1.3. Mexico
      • 5.6.2.2. Europe
        • 5.6.2.2.1. Western Europe
          • 5.6.2.2.1.1. The UK
          • 5.6.2.2.1.2. Germany
          • 5.6.2.2.1.3. France
          • 5.6.2.2.1.4. Italy
          • 5.6.2.2.1.5. Spain
          • 5.6.2.2.1.6. Rest of Western Europe
        • 5.6.2.2.2. Eastern Europe
          • 5.6.2.2.2.1. Poland
          • 5.6.2.2.2.2. Russia
          • 5.6.2.2.2.3. Rest of Eastern Europe
      • 5.6.2.3. Asia Pacific
        • 5.6.2.3.1. China
        • 5.6.2.3.2. India
        • 5.6.2.3.3. Japan
        • 5.6.2.3.4. South Korea
        • 5.6.2.3.5. Australia & New Zealand
        • 5.6.2.3.6. ASEAN
            • 5.6.2.3.6.1.1. Indonesia
            • 5.6.2.3.6.1.2. Malaysia
            • 5.6.2.3.6.1.3. Thailand
            • 5.6.2.3.6.1.4. Singapore
            • 5.6.2.3.6.1.5. Rest of ASEAN
        • 5.6.2.3.7. Rest of Asia Pacific
      • 5.6.2.4. Middle East & Africa
        • 5.6.2.4.1. UAE
        • 5.6.2.4.2. Saudi Arabia
        • 5.6.2.4.3. South Africa
        • 5.6.2.4.4. Rest of MEA
      • 5.6.2.5. South America
        • 5.6.2.5.1. Argentina
        • 5.6.2.5.2. Brazil
        • 5.6.2.5.3. Rest of South America

Chapter 6. North America Targeted Cancer Therapy Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Therapy Type
    • 6.2.2. By Disease Indication
    • 6.2.3. By End User
    • 6.2.4. By Country

Chapter 7. Europe Targeted Cancer Therapy Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Therapy Type
    • 7.2.2. By Disease Indication
    • 7.2.3. By End User
    • 7.2.4. By Country

Chapter 8. Asia Pacific Targeted Cancer Therapy Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Therapy Type
    • 8.2.2. By Disease Indication
    • 8.2.3. By End User
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Targeted Cancer Therapy Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Therapy Type
    • 9.2.2. By Disease Indication
    • 9.2.3. By End User
    • 9.2.4. By Country

Chapter 10. South America Targeted Cancer Therapy Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Therapy Type
    • 10.2.2. By Disease Indication
    • 10.2.3. By End User
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Agenus, Inc.
  • 11.2. Amgen, Inc.
  • 11.3. Arcus Biosciences, Inc.
  • 11.4. AstraZeneca Plc.
  • 11.5. Aurinia Pharmaceuticals Inc.
  • 11.6. Celdara Medical LLC
  • 11.7. F. Hoffmann-La Roche & Co.
  • 11.8. Genentech, Inc.
  • 11.9. Gilead Sciences, Inc.
  • 11.10. Nektar Therapeutics Inc.
  • 11.11. Pfizer, Inc.
  • 11.12. Serena Therapeutics Inc.
  • 11.13. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators